William Blair Issues Negative Forecast for BMY Earnings

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Research analysts at William Blair cut their Q1 2026 EPS estimates for shares of Bristol-Myers Squibb in a research report issued to clients and investors on Wednesday, February 19th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $1.57 for the quarter, down from their prior forecast of $1.58. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.74 per share. William Blair also issued estimates for Bristol-Myers Squibb's Q2 2026 earnings at $1.58 EPS, Q4 2026 earnings at $1.60 EPS, FY2026 earnings at $6.40 EPS and FY2029 earnings at $5.07 EPS.

A number of other research firms have also issued reports on BMY. Morgan Stanley raised their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an "underweight" rating in a research report on Tuesday, November 12th. Leerink Partnrs raised shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, November 12th. Jefferies Financial Group raised shares of Bristol-Myers Squibb from a "hold" rating to a "buy" rating and raised their price target for the stock from $63.00 to $70.00 in a research report on Monday, December 16th. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Finally, Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a research report on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of "Hold" and a consensus target price of $57.86.

Bristol-Myers Squibb Stock Performance

BMY stock traded up $0.06 during trading on Friday, reaching $55.85. The company had a trading volume of 11,100,311 shares, compared to its average volume of 10,886,042. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.10. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market cap of $113.33 billion, a price-to-earnings ratio of -12.63, a price-to-earnings-growth ratio of 2.04 and a beta of 0.45. The firm has a 50-day simple moving average of $56.99 and a 200-day simple moving average of $54.30.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Reston Wealth Management LLC acquired a new position in Bristol-Myers Squibb in the third quarter valued at about $25,000. Hollencrest Capital Management lifted its position in Bristol-Myers Squibb by 61.3% in the third quarter. Hollencrest Capital Management now owns 492 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 187 shares during the last quarter. Pinney & Scofield Inc. acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $25,000. Kennebec Savings Bank acquired a new position in Bristol-Myers Squibb in the third quarter valued at about $28,000. Finally, Fairway Wealth LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $28,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Activity

In other news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction dated Friday, February 14th. The shares were purchased at an average price of $54.84 per share, with a total value of $99,973.32. Following the transaction, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. The trade was a 2.94 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were given a dividend of $0.62 per share. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.60. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 annualized dividend and a dividend yield of 4.44%. Bristol-Myers Squibb's payout ratio is presently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.